To determine IGF2BP2 expression in T-ALL patients, the assessment of human leukemia databases (GSE48558) showed a significant increase in IGF2BP2 and IGF2BP3 expression in T-ALL cells compared with that in normal T cells, whereas YTHDC1, YTHDC2 and METTL16 were decreased; IGF2BP1 or other m6A modification enzymes were no significantly different (Fig. 1B, Supplementary Fig. 1A and Supplementary Fig. 2). Here, METTL16 is linked to acute lymphoblastic leukemia.